Cross-Sector entity
ATG-201 is most often covered alongside UCB, which appears in 3 of these 3 stories. Across a 17-day span, the pace is roughly 1.2 stories per week. The busiest single day carried 2. Coverage clusters in pharma, which accounts for 2 of those 3, with the remainder spread across 1 other category.
3 verified stories tracked
Last mentioned: Mar 20, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
ATG-201 is most often covered alongside UCB, which appears in 3 of these 3 stories. Across a 17-day span, the pace is roughly 1.2 stories per week. The busiest single day carried 2. Coverage clusters in pharma, which accounts for 2 of those 3, with the remainder spread across 1 other category. We currently track 3 Cross-Sector stories that mention ATG-201, published between March 4, 2026 and March 20, 2026. The tracked stories average 2.3 original sources each.
Computed from the 3 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering ATG-201. Shared-story counts are live from our verified record — not editorial picks.
Profitability Target
Antengene aims to achieve its first full year of profitability.
AACR 2026
Antengene scheduled to present data on next-generation ADCs and TCEs.
Clinical Filings Target
Antengene plans to submit CTAs for ATG-201 in China and Australia by the end of Q1 2026.
2025 FY Results
Company announces full-year results and confirms shift toward 2026 profitability.
Investor Briefings
Antengene hosts conference calls in Chinese and English to discuss the UCB partnership.
UCB Partnership
Antengene enters into a global license agreement with UCB for ATG-201 for $60M upfront.
Global License Agreement
Antengene and UCB announce exclusive worldwide licensing deal for ATG-201.
Regulatory Filings
Planned submission of clinical trial applications for ATG-201 in China and Australia.
Antengene Corporation has reported its 2025 full-year financial results, highlighted by the first successful out-licensing of its proprietary T-cell engager (TCE) platform. This strategic milestone validates the company's R&D capabilities and establishes a clear path toward projected profitability by 2026.
Antengene has granted UCB exclusive global rights to ATG-201, a CD19/CD3 bispecific T-cell engager, in a deal worth up to $1.18 billion. The partnership leverages Antengene's AnTenGager platform to target B-cell-driven autoimmune diseases, marking a major strategic expansion for both firms.
UCB has secured exclusive global rights to Antengene's ATG-201, a CD19/CD3 bispecific T-cell engager targeting autoimmune diseases. The agreement includes $80 million in upfront payments and potential milestones exceeding $1.1 billion, validating Antengene's AnTenGager platform.
Source: admin (in) · admin (in)
